In this episode of MedSpa Mayhem, Dr. Kate Dee discusses the turmoil surrounding the weight loss drugs semaglutide and tirzepatide, focusing on recent FDA regulations and the ongoing legal battles involving compounding pharmacies. Dr. Dee explains the benefits and side effects of these drugs, particularly the differences between semaglutide and tirzepatide, and shares her personal and professional experiences with them. The episode also covers the impact of FDA decisions on med spas across the country, potential shifts in drug availability, and the ethical and legal dilemmas faced by practitioners. Furthermore, Dr. Dee provides an update on Dr. Sagan’s ongoing lawsuit with Eli Lilly for false advertising and trademark infringement.

Takeaways:

• Tirzepatide has been declared no longer in shortage by the FDA
• Compounding pharmacies have limited time to sell what they have on hand
• The GLP-1 Weight Loss industry is in chaos, and the drugs will likely be in very short supply and costs are likely to rise

Email Dr. Kate Dee at [email protected]

Check out the Medspa Mayhem website for

• More about Dr. Dee

• Upcoming appearances

• Links to buy the book on Bookshop, B&N, Amazon

• Press and Podcast info

Glow Medispa in Seattle, WA

Purchase Medspa Mayhem on Amazon

Chapters

01:10 The Tirzepatide Saga

02:37 Compounding Pharmacies and Legal Issues

06:22 FDA Announcements and Lawsuits

11:05 Personal Experiences and Future Predictions

15:22 Updates on Dr. Sagan and Conclusion